Lundin Law PC, a shareholder rights firm announces a class action lawsuit against SCYNEXIS, Inc. (“SCYNEXIS” or the “Company”) (Nasdaq: SCYX). Investors who purchased or otherwise acquired SCYNEXIS shares between May 2, 2014, and March 2, 2017, inclusive (the “Class Period”), are encouraged to contact the firm in advance of the May 8, 2017 lead plaintiff deadline.
To participate in this class action lawsuit, click here, or call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at brian@lundinlawpc.com.
No class has been certified in the above action yet. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.
SCYNEXIS announced that the U.S. Food and Drug Administration ("FDA") has placed a hold on clinical trials for the intravenous formulation of the Company’s lead product candidate SCY-078 “until the FDA completes a review of all available pre-clinical and clinical data.” The Company explained to shareholders that “[t]he clinical hold decision was issued by the FDA following a review of three mild-to-moderate thrombotic events in healthy volunteers receiving the IV formulation of SCY-078 at the highest doses and highest concentrations in a Phase 1 study.”
When this news was revealed to the investing public, the value of SCYNEXIS dropped, causing investors harm.
Lundin Law PC was established by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders' rights.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170321006589/en/
Contacts:
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile:
888-713-1125
brian@lundinlawpc.com
